GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,510.80-29.20 (-1.90%)
At close: 4:35PM GMT
| Previous close | 1,540.00 |
| Open | 1,512.00 |
| Bid | 1,502.00 x 0 |
| Ask | 1,530.00 x 0 |
| Day's range | 1,503.00 - 1,526.80 |
| 52-week range | 1,190.80 - 1,604.40 |
| Volume | 9,055,403 |
| Avg. volume | 8,115,100 |
| Market cap | 76.02B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 17.71 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (5.30%) |
| Ex-dividend date | 18 Nov 2021 |
| 1y target est | N/A |
- Business Wire
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
LONDON, September 28, 2021--FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
- Business Wire
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
LONDON, July 29, 2021--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps.
- Business Wire
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra long-acting" medicines for HIV
LONDON & SAN DIEGO, Jun 22, 2021--ViiV HC and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to develop ultra-long-acting HIV medicines
© 2021 Yahoo. All rights reserved.
